Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siming Li

Showing results (231-240 of 247) with videos related to

Pageof 25
Sort By:
Theranostics|March 15, 2019
MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK PathwaysMeng Ma, Jie Dai, Huan Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Theranostics|May 13, 2022
Erratum: MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: ErratumMeng Ma, Jie Dai, Huan Tang, et al.
Journal of Hematology & Oncology|January 16, 2019
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patientsBixia Tang, Xieqiao Yan, Xinan Sheng, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapyJie Dai, Xue Bai, Xuan Gao, et al.
Annals of Surgical Oncology|April 10, 2022
An Evidence-Based Staging System for Mucosal Melanoma: A ProposalChuanLiang Cui, Bin Lian, XiaoShi Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous MelanomaJiayi Yu, Junya Yan, Qian Guo, et al.
Nature Communications|May 15, 2026
A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanomaLili Mao, Yumei Lai, Hong Zheng, et al.
Annals of Surgical Oncology|November 24, 2020
Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic EraRichard J Straker, Yun Song, James Sun, et al.
JAMA Oncology|June 1, 2023
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical TrialLili Mao, Bin Lian, Caili Li, et al.
Pageof 25

Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
Theranostics|March 15, 2019
MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK PathwaysMeng Ma, Jie Dai, Huan Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Theranostics|May 13, 2022
Erratum: MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: ErratumMeng Ma, Jie Dai, Huan Tang, et al.
Journal of Hematology & Oncology|January 16, 2019
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patientsBixia Tang, Xieqiao Yan, Xinan Sheng, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapyJie Dai, Xue Bai, Xuan Gao, et al.
Annals of Surgical Oncology|April 10, 2022
An Evidence-Based Staging System for Mucosal Melanoma: A ProposalChuanLiang Cui, Bin Lian, XiaoShi Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous MelanomaJiayi Yu, Junya Yan, Qian Guo, et al.
Nature Communications|May 15, 2026
A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanomaLili Mao, Yumei Lai, Hong Zheng, et al.
Annals of Surgical Oncology|November 24, 2020
Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic EraRichard J Straker, Yun Song, James Sun, et al.
JAMA Oncology|June 1, 2023
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical TrialLili Mao, Bin Lian, Caili Li, et al.
Pageof 25